Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for inflammatory dilated cardiomyopathy
2020-005507-39Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of anakinra in inflammatory cardiomyopathy and dilated cardiomyopathy (DCM), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Improvement in left ventricular ejection fraction at 4 weeks. Started Jun 2021; status: active.
02
Drugs
anakinra
03
Conditions
inflammatory cardiomyopathydilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2020-005507-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005507-39.